Salt Lake City, January 10, 2022 /GlobeNewswire/ — CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of California Neuroscience Research (“CenExel CNR”), a clinical research facility in Los Angeles with two decades of experience in neurological...
News at CenExel
Preferences of the Opioid Use Disorder Patient: Clinical Trial Methodologies and COVID19 Mitigations that Motivate Participation
CenExel is proud to highlight the poster presented at the Annual International/Canadian Society of Addiction Medicine, November 2020, Virtual Meeting. ABSTRACT Introduction: The need to conduct clinical trials for the treatment of opioid use disorder (OUD) cannot be...
Taming the Placebo Effect in Depression Clinical Trials: The Methodological Implementation of a Placebo-Control Reminder Script
CenExel is proud to highlight the poster presented at the Annual International Society for CNS Clinical Trials and Methodology (ISCTM) Meeting, February 2019, Washington, DC. ABSTRACT Introduction: Although the placebo effect continues to persist within depressive...